Expanding treatment options for millions of adults facing kidney decline could significantly alter the trajectory of cardiovascular health and mortality risk. Current therapeutic approaches for chronic kidney disease have largely focused on diabetic populations, leaving substantial gaps in care for non-diabetic patients experiencing progressive kidney function loss.
The FIND-CKD trial evaluated finerenone, a selective mineralocorticoid receptor antagonist, in 5,734 adults with chronic kidney disease who did not have diabetes. Over a median follow-up of 3.4 years, participants receiving finerenone demonstrated a 23% reduction in the composite primary endpoint of sustained decline in estimated glomerular filtration rate, kidney failure, or cardiovascular death compared to placebo. The drug showed particular efficacy in slowing kidney function decline, with treatment effects becoming apparent within the first year.
This represents a notable expansion of finerenone's clinical utility beyond its established role in diabetic kidney disease. The mineralocorticoid pathway plays a crucial role in kidney fibrosis and inflammation regardless of diabetes status, suggesting the mechanistic rationale extends across different chronic kidney disease etiologies. However, the study population was predominantly white and male, potentially limiting generalizability to more diverse populations.
The findings could reshape nephrology practice by providing evidence-based treatment for the substantial population of non-diabetic chronic kidney disease patients who previously had limited targeted therapeutic options. While promising, the results require careful consideration of individual patient factors, including potassium monitoring requirements and the drug's established side effect profile from diabetes studies.